Apollo Hospitals Enterprise Ltd (APOLLOHOSP) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↑

+0.64%

Short-term demand accumulation with positive intraday momentum.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 41.5%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 21.2%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹8,302.86

200-Day DMA ● Overlay

₹7,700.58

14-Day RSI ● Overlay

54.2 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹1.13 Lakh Cr

Large cap

Stock P/E (TTM) Valuation

53.9x

Price / EPS

Book Value (₹) Assets

₹659.0

P/B: 12.0x

ROE (%) Quality

21.2%

Net Profit / Equity

ROCE (%) Efficiency

17.4%

EBIT / Capital

Dividend Yield Yield

0.25%

Face Value: ₹10

Debt / Equity Solvency

0.90x

Manageable

EPS (TTM) Per Share

₹146.52

Trailing 12M

OPM (%) Spread

15.0%

EBITDA Margin

Free Cash Flow Cash

₹925.00 Cr

CFO - Capex

About Apollo Hospitals Enterprise Ltd

Apollo Hospitals Enterprise Ltd (APOLLOHOSP) is a leading Indian enterprise operating in the Healthcare & Pharma sector.

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 10.8% × Turnover: 0.85x × Leverage: 1.9x = ROE: 21.2%

✓ Company Strengths (Pros)

• Company has a stellar track record of return on equity (ROE of 21.2%).
• TickerPulse fundamental algorithm rates overall quality at 80/100.

⚠ Key Considerations & Risks (Cons)

• Company has a high debt-to-equity ratio of 0.90x.
• Stock is trading at a premium of 12.0x its book value.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹26,430 Cr

Latest PAT

₹2,172 Cr

EPS (TTM)

₹146.52

OPM %

15.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹4,418 Cr	₹4,847 Cr	₹4,851 Cr	₹4,944 Cr	₹5,086 Cr	₹5,589 Cr	₹5,527 Cr	₹5,592 Cr	₹5,842 Cr	₹6,304 Cr	₹6,477 Cr	₹6,606 Cr	₹7,044 Cr
Operating Profit (EBITDA)	₹509.00 Cr	₹628.00 Cr	₹614.00 Cr	₹640.00 Cr	₹675.00 Cr	₹816.00 Cr	₹762.00 Cr	₹770.00 Cr	₹852.00 Cr	₹941.00 Cr	₹965.00 Cr	₹1,011 Cr	₹1,092 Cr
OPM %	12.0%	13.0%	13.0%	13.0%	13.0%	15.0%	14.0%	14.0%	15.0%	15.0%	15.0%	15.0%	16.0%
Interest Expense	₹106.00 Cr	₹111.00 Cr	₹113.00 Cr	₹119.00 Cr	₹116.00 Cr	₹118.00 Cr	₹110.00 Cr	₹115.00 Cr	₹108.00 Cr	₹110.00 Cr	₹113.00 Cr	₹119.00 Cr	₹120.00 Cr
Depreciation	₹167.00 Cr	₹163.00 Cr	₹167.00 Cr	₹190.00 Cr	₹177.00 Cr	₹184.00 Cr	₹185.00 Cr	₹211.00 Cr	₹215.00 Cr	₹218.00 Cr	₹219.00 Cr	₹224.00 Cr	₹235.00 Cr
Profit before Tax (PBT)	₹270.00 Cr	₹379.00 Cr	₹363.00 Cr	₹368.00 Cr	₹430.00 Cr	₹557.00 Cr	₹536.00 Cr	₹516.00 Cr	₹583.00 Cr	₹675.00 Cr	₹682.00 Cr	₹722.00 Cr	₹799.00 Cr
Net Profit (PAT)	₹173.00 Cr	₹249.00 Cr	₹254.00 Cr	₹258.00 Cr	₹316.00 Cr	₹396.00 Cr	₹379.00 Cr	₹414.00 Cr	₹441.00 Cr	₹494.00 Cr	₹516.00 Cr	₹551.00 Cr	₹610.00 Cr
EPS in ₹	₹11.59	₹16.20	₹17.06	₹17.65	₹21.23	₹26.34	₹25.89	₹27.10	₹30.10	₹33.19	₹34.93	₹36.81	₹40.39

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹5,129 Cr	₹6,150 Cr	₹7,256 Cr	₹8,243 Cr	₹9,617 Cr	₹11,247 Cr	₹10,560 Cr	₹14,663 Cr	₹16,612 Cr	₹19,059 Cr	₹21,794 Cr	₹25,228 Cr	₹26,430 Cr
Expenses	₹4,392 Cr	₹5,465 Cr	₹6,522 Cr	₹7,442 Cr	₹8,548 Cr	₹9,656 Cr	₹9,420 Cr	₹12,474 Cr	₹14,548 Cr	₹16,665 Cr	₹18,761 Cr	₹21,449 Cr	₹22,420 Cr
Operating Profit	₹737.00 Cr	₹684.00 Cr	₹734.00 Cr	₹801.00 Cr	₹1,070 Cr	₹1,591 Cr	₹1,140 Cr	₹2,189 Cr	₹2,065 Cr	₹2,394 Cr	₹3,033 Cr	₹3,779 Cr	₹4,010 Cr
OPM %	14%	11%	10%	10%	11%	14%	11%	15%	12%	13%	14%	15%	15%
Interest	₹118.00 Cr	₹180.00 Cr	₹257.00 Cr	₹295.00 Cr	₹327.00 Cr	₹533.00 Cr	₹449.00 Cr	₹379.00 Cr	₹381.00 Cr	₹449.00 Cr	₹458.00 Cr	₹450.00 Cr	₹462.00 Cr
Depreciation	₹212.00 Cr	₹264.00 Cr	₹314.00 Cr	₹359.00 Cr	₹396.00 Cr	₹620.00 Cr	₹573.00 Cr	₹601.00 Cr	₹615.00 Cr	₹687.00 Cr	₹758.00 Cr	₹876.00 Cr	₹896.00 Cr
Profit before Tax	₹455.00 Cr	₹332.00 Cr	₹222.00 Cr	₹171.00 Cr	₹373.00 Cr	₹660.00 Cr	₹221.00 Cr	₹1,578 Cr	₹1,144 Cr	₹1,380 Cr	₹2,039 Cr	₹2,661 Cr	₹2,877 Cr
Net Profit	₹335.00 Cr	₹235.00 Cr	₹131.00 Cr	₹60.00 Cr	₹200.00 Cr	₹432.00 Cr	₹137.00 Cr	₹1,108 Cr	₹844.00 Cr	₹935.00 Cr	₹1,505 Cr	₹2,003 Cr	₹2,172 Cr
EPS in Rs	24.43	16.99	15.88	8.44	16.96	32.70	10.46	73.42	56.97	62.50	100.56	135.04	145.32

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹70.00 Cr	₹70.00 Cr	₹70.00 Cr	₹70.00 Cr	₹70.00 Cr	₹70.00 Cr	₹72.00 Cr	₹72.00 Cr	₹72.00 Cr	₹72.00 Cr	₹72.00 Cr	₹72.00 Cr
Reserves & Surplus	₹3,102 Cr	₹3,262 Cr	₹3,244 Cr	₹3,182 Cr	₹3,264 Cr	₹3,270 Cr	₹4,531 Cr	₹5,551 Cr	₹6,126 Cr	₹6,864 Cr	₹8,140 Cr	₹9,408 Cr
Borrowings (Debt)	₹1,992 Cr	₹2,834 Cr	₹3,125 Cr	₹3,427 Cr	₹3,673 Cr	₹3,596 Cr	₹4,160 Cr	₹4,068 Cr	₹4,332 Cr	₹5,333 Cr	₹7,864 Cr	₹8,493 Cr
Total Liabilities	₹6,459 Cr	₹7,360 Cr	₹8,103 Cr	₹8,596 Cr	₹9,166 Cr	₹11,289 Cr	₹11,392 Cr	₹13,261 Cr	₹14,416 Cr	₹16,742 Cr	₹20,644 Cr	₹22,183 Cr
Fixed Assets	₹3,244 Cr	₹3,997 Cr	₹4,591 Cr	₹4,773 Cr	₹4,982 Cr	₹7,432 Cr	₹6,778 Cr	₹8,296 Cr	₹8,520 Cr	₹9,664 Cr	₹10,988 Cr	₹12,272 Cr
Total Assets	₹6,459 Cr	₹7,360 Cr	₹8,103 Cr	₹8,596 Cr	₹9,166 Cr	₹11,289 Cr	₹11,392 Cr	₹13,261 Cr	₹14,416 Cr	₹16,742 Cr	₹20,644 Cr	₹22,183 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	₹470.00 Cr	₹597.00 Cr	₹623.00 Cr	₹537.00 Cr	₹905.00 Cr	₹1,293 Cr	₹1,265 Cr	₹1,696 Cr	₹1,377 Cr	₹1,920 Cr	₹2,136 Cr	₹2,856 Cr
Cash from Investing (CFI)	-₹759.00 Cr	-₹888.00 Cr	-₹1,152 Cr	-₹405.00 Cr	-₹711.00 Cr	-₹289.00 Cr	-₹880.00 Cr	-₹747.00 Cr	-₹857.00 Cr	-₹1,537 Cr	-₹3,383 Cr	-₹2,145 Cr
Cash from Financing (CFF)	₹392.00 Cr	₹330.00 Cr	₹477.00 Cr	-₹108.00 Cr	-₹215.00 Cr	-₹910.00 Cr	-₹340.00 Cr	-₹792.00 Cr	-₹633.00 Cr	-₹311.00 Cr	₹1,319 Cr	-₹478.00 Cr
Free Cash Flow (FCF)	-₹396.00 Cr	-₹393.00 Cr	-₹46.00 Cr	-₹84.00 Cr	₹233.00 Cr	₹782.00 Cr	₹984.00 Cr	₹1,044 Cr	₹252.00 Cr	₹785.00 Cr	₹439.00 Cr	₹925.00 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	43	36	38	37	39	33	46	44	49	48	51	50
Inventory Days	50	49	47	51	46	49	16	21	17	17	16	15
Cash Conversion Cycle (Days)	34	19	34	33	29	22	-12	-14	-16	-23	-6	3
ROCE %	12%	9%	8%	7%	10%	14%	8%	17%	14%	15%	17%	17%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹2,237.76 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹8,604.00

DCF Fair Value

₹2,237.76

Graham Number

₹1,473.95

Margin of Safety

-78%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹2,237.76

Premium / Overvalued (Margin: -78%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹2,178	₹2,158	₹2,138	₹2,119
10%	₹2,218	₹2,198	₹2,178	₹2,159
12%	₹2,258	₹2,238	₹2,218	₹2,198
14%	₹2,299	₹2,278	₹2,257	₹2,237

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹2,238	Fairly Valued
Benjamin Graham Number	₹1,474	Market Priced
Historical Sector P/E	₹3,223	Premium
EV / EBITDA Multiplier	₹9,034	In-Line
Free Cash Flow Yield Model	₹8,432	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 6/9 (Stable Financials)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

6 / 9 Pass

Altman Z-Score

3.3 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Elevated leverage at 0.90x

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 15.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

28.02%

FIIs (Foreign)

41.49%

DIIs (Domestic)

23.72%

Government

0.15%

Public / Retail

6.53%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	29.33%	29.33%	29.33%	29.33%	29.33%	29.33%	29.34%	29.34%	28.02%	28.02%	28.02%	28.02%
+ FIIs (Foreign Portfolio)	46.15%	46.25%	45.63%	43.92%	45.37%	45.27%	42.74%	43.49%	44.20%	43.54%	42.62%	41.49%
+ DIIs (Mutual Funds / Insurance)	18.59%	18.87%	19.55%	21.13%	19.94%	19.97%	22.29%	21.34%	21.12%	21.50%	22.76%	23.72%
+ Public (Retail & HNIs)	5.68%	5.32%	5.26%	5.38%	5.12%	5.21%	5.41%	5.61%	6.43%	6.71%	6.39%	6.53%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

APOLLOHOSP Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

APOLLOHOSP Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

APOLLOHOSP Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹11,013.12

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹9,636.48

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 54x P/E.

🐻 Bear Case (15%) -12.0%

₹7,571.52

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 20:46 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Target Stock	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr
Dr Reddys Laboratories Ltd (DRREDDY)	Active Ingredients & Biosimilars	₹1,377.00	-0.58%	30.6x	11.2%	13.0%	0.20	₹98,492 Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	20:46:40 IST	✓ Live Sync
Financial Statements (10Y)	Apollo Hospitals Enterprise Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

Apollo Hospitals Enterprise Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About Apollo Hospitals Enterprise Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title